Peroxisome proliferator-activated receptor-γ activation inhibits tumor metastasis by antagonizing Smad3-mediated epithelial-mesenchymal transition AK Reka, H Kurapati, VR Narala, G Bommer, J Chen, TJ Standiford, ... Molecular cancer therapeutics 9 (12), 3221-3232, 2010 | 172 | 2010 |
Leukotriene B4 is a physiologically relevant endogenous peroxisome proliferator-activated receptor-α agonist VR Narala, RK Adapala, MV Suresh, TG Brock, M Peters-Golden, ... Journal of Biological Chemistry 285 (29), 22067-22074, 2010 | 165 | 2010 |
Irisin/FNDC5-An updated review. K Panati, Y Suneetha, VR Narala European Review for Medical & Pharmacological Sciences 20 (4), 2016 | 145 | 2016 |
Curcumin inhibits fibrosis-related effects in IPF fibroblasts and in mice following bleomycin-induced lung injury MR Smith, SR Gangireddy, VR Narala, CM Hogaboam, TJ Standiford, ... American journal of physiology-lung cellular and molecular physiology 298 (5 …, 2010 | 142 | 2010 |
Sepsis-induced inhibition of neutrophil chemotaxis is mediated by activation of peroxisome proliferator-activated receptor-γ RC Reddy, VR Narala, VG Keshamouni, JE Milam, MW Newstead, ... Blood, The Journal of the American Society of Hematology 112 (10), 4250-4258, 2008 | 115 | 2008 |
Role of farnesoid X receptor in inflammation and resolution FB Shaik, DVR Prasad, VR Narala Inflammation Research 64, 9-20, 2015 | 81 | 2015 |
Pioglitazone is as effective as dexamethasone in a cockroach allergen-induced murine model of asthma VR Narala, R Ranga, MR Smith, AA Berlin, TJ Standiford, NW Lukacs, ... Respiratory research 8, 1-10, 2007 | 63 | 2007 |
Curcumin nanotechnologies and its anticancer activity PA Subramani, K Panati, VR Narala Nutrition and cancer 69 (3), 381-393, 2017 | 57 | 2017 |
Development of new probiotic foods—a case study on probiotic juices VR Lebaka, YJ Wee, VR Narala, VK Joshi Therapeutic, probiotic, and unconventional foods, 55-78, 2018 | 55 | 2018 |
Curcumin is not a ligand for peroxisome proliferator-activated receptor-γ VR Narala, MR Smith, RK Adapala, R Ranga, K Panati, BB Moore, T Leff, ... Gene therapy & molecular biology 13 (1), 20, 2009 | 54 | 2009 |
Akap1 genetic deletion increases the severity of hyperoxia-induced acute lung injury in mice VR Narala, J Fukumoto, H Hernández-Cuervo, SS Patil, S Krishnamurthy, ... American Journal of Physiology-Lung Cellular and Molecular Physiology 314 (5 …, 2018 | 51 | 2018 |
Chenodeoxycholic acid attenuates ovalbumin-induced airway inflammation in murine model of asthma by inhibiting the TH2 cytokines FB Shaik, K Panati, VR Narasimha, VR Narala Biochemical and Biophysical Research Communications 463 (4), 600-605, 2015 | 40 | 2015 |
The role of nitrated fatty acids and peroxisome proliferator-activated receptor gamma in modulating inflammation VR Narala, PA Subramani, VR Narasimha, FB Shaik, K Panati international immunopharmacology 23 (1), 283-287, 2014 | 38 | 2014 |
Nano-and microscale drug delivery systems: Design and fabrication AM Grumezescu William Andrew, 2017 | 37 | 2017 |
Recent advances in the extraction and characterization of seed polysaccharides, and their bioactivities: A review S Muthusamy, GP Udayakumar, VR Narala Bioactive Carbohydrates and Dietary Fibre 26, 100276, 2021 | 30 | 2021 |
The role of club cell phenoconversion and migration in idiopathic pulmonary fibrosis J Fukumoto, R Soundararajan, J Leung, R Cox Jr, S Mahendrasah, ... Aging (Albany NY) 8 (11), 3091, 2016 | 30 | 2016 |
Challenges of curcumin bioavailability: novel aerosol remedies PA Subramani, VR Narala Natural product communications 8 (1), 1934578X1300800129, 2013 | 29 | 2013 |
Nanostructures for curcumin delivery: possibilities and challenges PA Subramani, K Panati, VR Lebaka, DD Reddy, VR Narala Nano-and Microscale Drug Delivery Systems, 393-418, 2017 | 28 | 2017 |
Increased yield of high purity recombinant human interferon-γ utilizing reversed phase column chromatography PK Reddy, SG Reddy, VR Narala, SS Majee, S Konda, S Gunwar, ... Protein expression and purification 52 (1), 123-130, 2007 | 26 | 2007 |
COVID-19 outbreak: an update on therapeutic options K Panati, VR Narala SN Comprehensive Clinical Medicine 2 (4), 379-380, 2020 | 24 | 2020 |